Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of FM101 in Healthy Volunteers
NCT03879928Phase 1Completed
- Sponsor
- Future Medicine
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FM101 in Glaucoma and Nonalcoholic steatohepatitis (NASH) (13 arms), sponsored by Future Medicine. Primary endpoints: Number, severity, and type of Treatment Emergent Adverse Events (TEAEs), Change in clinical laboratory values and 7 more. Started Jan 2019; status: completed.
02
Drugs
FM101
03
Conditions
GlaucomaNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03879928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879928.